- Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 to complete its planned phase 1 and phase 2 clinical trials
- Algernon has appointed Dr. Anthony Rudd and Dr. Robert Simister, as medical consultants to the company’s DMT stroke clinical research program
- Both UK-based doctors have extensive backgrounds in stroke management as well as clinical care and stroke research
- They will help guide the phase 2 acute stroke and post stroke therapy clinical trials planned to begin in the U.K. following the completion of the phase 1 trial
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.67 per share
Algernon Pharmaceuticals (AGN) has manufactured a supply of clinical-grade AP-188 DMT for its planned phase 1 and phase 2 clinical trials.
The company believes it has produced a sufficient supply of cGMP DMT to complete its planned phase 1 and phase 2 clinical trials.
Algernon has appointed Dr. Anthony Rudd and Dr. Robert Simister, as medical consultants to the company’s DMT stroke clinical research program. Both Dr. Rudd and Dr. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.
Their primary responsibility will be to help guide the phase 2 acute stroke and post-stroke therapy clinical trials planned to begin in the U.K. in the latter part of 2022 following the completion of the phase 1 trial.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$3.67 per share.
